Skip to content
Peptilyze
CompoundsShopsCompareGuidesMethod
Metabolic research

Cagrilintide studies

164 journal papers mention Cagrilintide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Cagrilintide is safe, effective or approved for any use.

Compare Cagrilintide prices, from €59.95 →

Papers
164
113 articles, 51 reviews
Earliest paper
2021
Most papers in 2026 (72)
Open access
58%
free to read somewhere
Reviews
31%
of all papers listed

What kind of studies

Of 105 papers in PubMed that mention Cagrilintide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials15
  • Other clinical trials0
  • Meta-analyses and systematic reviews11
  • Other reviews50
  • Case reports0
  • Animal studies only6
  • Studies in humans64

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Registered clinical studies

Studies on ClinicalTrials.gov that mention Cagrilintide in their intervention details. A registration says a study is planned or running, not what it found.

Registered
44
Completed
24
Ongoing or planned
18
Phase 1
17
Phase 2
5
Phase 3
22
  1. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

    NCT07607587RecruitingPhase 1started 2026-05-29

  2. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    NCT06221969CompletedPhase 3started 2024-01-16

  3. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

    NCT06534411CompletedPhase 3started 2024-11-05

  4. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

    NCT07282613RecruitingPhase 3started 2026-08-04

  5. Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

    NCT07220759Active, not recruitingPhase 3started 2025-11-05

The five most recently updated studies. See all 44 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.

Papers per year

2021 to 2026, peak 72 papers in a year. The latest year may still be incomplete.

2021: 8 papers2022: 5 papers2023: 11 papers2024: 24 papers2025: 44 papers2026: 72 papers20212026

Where it is published

  1. Diabetes32 papers
  2. The Lancet8 papers
  3. Peptides5 papers
  4. Diabetes Obesity and Metabolism5 papers
  5. The Lancet Diabetes & Endocrinology5 papers

The papers

ShowAllOpen accessReviews

Most citedName in the title

  1. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

    Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen et al. · The Lancet · 2023

    Randomized trial · Phase 2Open access · CC BY-NC-ND333 citationsRead the open copy →

  2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

    Lone B Enebo, Kasper K. Berthelsen, Martin K. Kankam et al. · The Lancet · 2021

    Randomized trial · Phase 1316 citations

  3. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

    David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco et al. · The Lancet · 2021

    Randomized trial · Phase 2Open access278 citationsRead the open copy →

  4. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

    William Timothy Garvey, Matthias Blüher, Cynthia Karenina Osorto Contreras et al. · New England Journal of Medicine · 2025

    Randomized trial · Phase 3238 citations

  5. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Melanie Jane Davies, HARPREET SINGH BAJAJ, Christa Broholm et al. · New England Journal of Medicine · 2025

    Randomized trial · Phase 3145 citations

  6. Development of Cagrilintide, a Long-Acting Amylin Analogue

    Thomas Kruse, Jakob Lerche Hansen, Kirsten Dahl et al. · Journal of Medicinal Chemistry · 2021

    Study in humansOpen access · CC BY-NC-ND129 citationsRead the open copy →

  7. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

    Antonella M. D’Ascanio, Jamie Ann Mullally, William H. Frishman · Cardiology in Review · 2023

    Study in humans46 citations

  8. Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models

    Anna Thorsø Larsen, Khaled Elhady Mohamed, Nina Sonne et al. · Biomedicine & Pharmacotherapy · 2022

    Animal studyOpen access · CC BY-NC-ND38 citationsRead the open copy →

  9. Cagrilintide plus semaglutide for obesity management

    Sara Becerril, Gema Frühbeck · The Lancet · 2021

    Study in humans38 citations

  10. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

    Alexandra Oliveira Carvas, Andrea Stephanie Leuthardt, Patricia Kulka et al. · EBioMedicine · 2025

    Animal studyOpen access · CC BY25 citationsRead the open copy →

  11. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

    Deep Dutta, Lakshmi Nagendra, BG Harish et al. · Indian Journal of Endocrinology and Metabolism · 2024

    ReviewOpen access · CC BY-NC-SA17 citationsRead the open copy →

  12. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors

    Jianjun Cao, Matthew J. Belousoff, Rachel M. Johnson et al. · Nature Communications · 2025

    Study in humansOpen access · CC BY-NC-ND16 citationsRead the open copy →

  13. Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

    John B. Buse, HARPREET SINGH BAJAJ, Stine‐Mathilde Dalskov et al. · The Lancet Diabetes & Endocrinology · 2026

    Randomized trial · Phase 315 citations

  14. Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

    Julio Rosenstock, Liana K. Billings, Reena Gajria et al. · The Lancet · 2026

    Randomized trial · Phase 311 citations

  15. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

    Toshimasa Yamauchi, Niels‐Peter Becker, Christoffer Andersen Hagemann et al. · The Lancet Diabetes & Endocrinology · 2026

    Randomized trial · Phase 38 citations

  16. A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance

    Mette Q. Ludwig, Bernd Coester, Desiree Gordian et al. · Nature Metabolism · 2026

    Study in humansOpen access · CC BY5 citationsRead the open copy →

  17. Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

    Vanita R. Aroda, Raffaella Buzzetti, Stine‐Mathilde Dalskov et al. · The Lancet Diabetes & Endocrinology · 2026

    Randomized trial · Phase 35 citations

  18. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression

    Muhammad Ahmed, Muhammad Hassan, Muhammad Tahir et al. · Diabetes Obesity and Metabolism · 2026

    Meta-analysis5 citations

  19. Characterization of 0839 – A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide

    Sanaz Gabery, Tine Glendorf, Borja Ballarín-González et al. · Life Sciences · 2025

    Study in humansOpen access · CC BY-NC-ND3 citationsRead the open copy →

  20. Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials

    Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu-Khazneh et al. · Endocrinology Diabetes & Metabolism · 2026

    Study in humansOpen access · CC BY2 citationsRead the open copy →

  21. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis

    Hammad Rao, Sumet Kumar, Sheikh Muhammad Ebtehaj Ali et al. · Journal of Diabetes & Metabolic Disorders · 2026

    ReviewOpen access2 citationsRead the open copy →

  22. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors

    Yi-min Gu, Qingning Yuan, Xin Li et al. · Acta Pharmacologica Sinica · 2025

    Study in humansOpen access2 citationsRead the open copy →

  23. The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies

    Yuxin Wang, Zhien Feng, Lexiang Yu · The Innovation Medicine · 2025

    Open access · CC BY2 citationsRead the open copy →

  24. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants

    Maria B. N. Gabe, Rainard Fuhr, Angela Sinn et al. · Diabetes Obesity and Metabolism · 2024

    Randomized trialOpen access · CC BY-NC2 citationsRead the open copy →

  25. Cagrilintide Combined with Semaglutide: a new Approach for Treatment of Obesity and type 2 Diabetes

    Nasser Mikhail · Clinical Research and Clinical Trials · 2023

    Open access · CC BY2 citationsRead the open copy →

  26. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide

    Mette J. F. Nielsen, Niels‐Peter Becker, Helene H. Hansen Duus et al. · Clinical Pharmacokinetics · 2026

    Randomized trial · Phase 1Open access · CC BY-NC1 citationsRead the open copy →

  27. Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis

    Yange Meng, Ting Jin, Luping Ren et al. · Journal of Clinical Question · 2025

    Open access · CC BY1 citationsRead the open copy →

  28. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide

    Daniel A. Briere, ANNE LONG, DAWN M. BULLOCK et al. · Diabetes · 2025

    1 citations

  29. Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity

    Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski et al. · Journal of Education Health and Sport · 2026

    Open access · CC BY-NC-SARead the open copy →

  30. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

    Jonas Petersen, Christoffer Merrild, Stephanie Kjærulff Holm et al. · Nature Metabolism · 2026

    Animal studyOpen access · CC BYRead the open copy →

  31. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

    Mohammad Yaseen, Akmal Ameer, Zulfiqar Ali et al. · Annals of Medicine and Surgery · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  32. Cagrilintide–semaglutide: a new option for patients with type 2 diabetes

    André Jacques Scheen · The Lancet Diabetes & Endocrinology · 2026

  33. 1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys

    METTE HØY JENSEN, Samra Joke Sanni, Line Hartvig et al. · Diabetes · 2026

  34. 2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice

    Greta Lommi, SIMONE VIGOLO, Thomas A. Lutz et al. · Diabetes · 2026

  35. 26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS

    Ravi Medarametla, Ashok Runkana, Naga Praneeth Vakkalagadda et al. · Journal of the American College of Cardiology · 2026

    Open accessRead the open copy →

  36. 26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS

    Bara M. Hammadeh, Nesreen Alhamwi, Layan S. Aldib et al. · Journal of the American College of Cardiology · 2026

  37. Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis

    Ting Jin, Yange Meng, Luping Ren et al. · Journal of Clinical Question · 2025

    Open access · CC BYRead the open copy →

  38. #2426 Exploration of cagrilintide's mechanism of action in the kidney

    Vera Christine Wulfmeyer, Anja M. Billing, Sagar Bhayana et al. · Nephrology Dialysis Transplantation · 2025

  39. Exploration of Cagrilintide's Mechanism of Action in the Kidneys

    Vera Christine Wulfmeyer, Anja M. Billing, Sagar Bhayana et al. · Journal of the American Society of Nephrology · 2025

  40. 1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity

    Nikolaj Klausholt Bak, RACHEL GA YEON LEE, Angela Sinn et al. · Diabetes · 2025

LatestName in title or abstract

  1. EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW

    Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026

    ReviewOpen accessRead the open copy →

  2. Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis

    Chia Siang Kow, Abdullah Faiz Zaihan, Dinesh Sangarran Ramachandram et al. · Diabetes Obesity and Metabolism · 2026

    ReviewOpen access · CC BYRead the open copy →

  3. Dose-specific efficacy and safety of cagrisema in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

    Bilal Wazir Khan, Muhammad Huzaifa Khattak, Muhammad Yahya et al. · BMC Endocrine Disorders · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  4. The Hyperamylinemia–Inflammation–Coronary Artery Disease Axis in Type 2 Diabetes Mellitus: Exploring Amylin as a Potential Cardiometabolic Therapeutic Target

    International Journal of Drug Delivery Technology · 2026

    Open accessRead the open copy →

  5. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis

    Zehra Khatoon Rasool, Rajvi Shah, Ansharah E Zinnia Batool et al. · Frontiers in Endocrinology · 2026

    Meta-analysisOpen access · CC BYRead the open copy →

  6. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

    Matthew Aaron Cavender, Ania M. Jastreboff, ALICE Y.Y. CHENG et al. · American Heart Journal · 2026

    Open access · CC BYRead the open copy →

  7. Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats

    LISBETH MILLING PETERSEN, Filip Krag Knop, Carel Wynand le Roux et al. · Molecular Metabolism · 2026

    Open access · CC BY-NC-NDRead the open copy →

  8. Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

    Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  9. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus

    Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic et al. · Diabetes Therapy · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  10. Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity

    Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski et al. · Journal of Education Health and Sport · 2026

    Open access · CC BY-NC-SARead the open copy →

  11. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

    Jonas Petersen, Christoffer Merrild, Stephanie Kjærulff Holm et al. · Nature Metabolism · 2026

    Animal studyOpen access · CC BYRead the open copy →

  12. ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES

    Aleksandra Wielogórska, Olga Stasiak, Filip Kowalik et al. · International Journal of Innovative Technologies in Social Science · 2026

    Open access · CC BYRead the open copy →

  13. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review

    Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  14. Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials

    Chuhan Shao, Hanmo Lin, Jie Yu et al. · Diabetes Metabolic Syndrome and Obesity · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  15. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes

    Areesha Moiz, Kristian B. Filion, Aaron E. Samuels et al. · Annals of Internal Medicine · 2026

    Systematic review

  16. Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials

    Bilal Wazir Khan, Syed Asadullah Agha, Ihsan Qamar et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2026

    Review

  17. Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding

    Marcos J. Sanchez-Navarro, Carlie Zhang, Heath D. Schmidt et al. · Physiology & Behavior · 2026

    Animal studyOpen access · CC BY-NC-NDRead the open copy →

  18. Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs

    Sophia L. Fischer, Tito Borner · Pharmacological Research · 2026

    ReviewOpen access · CC BYRead the open copy →

  19. Amycretin in the Treatment of Obesity: Hormonal Mechanisms, Clinical Evidence, and Therapeutic Perspectives of the New Generation of Incretin Agonists

    Carolina Fátima Gioia Nava, Jaimiro Azevedo de Aquino Filho, Digilany Aparecida de Souza Lemes et al. · International Journal of Health Science · 2026

    Open accessRead the open copy →

  20. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials

    Deshi Chen, Bing Ma, Hao Sun et al. · BMJ Medicine · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  21. A novel unimolecular GLP1 and amylin receptor agonist for glucose and weight control

    Elaine Chow, Zhengli Bai · The Lancet · 2026

  22. Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

    Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen et al. · Diabetes Obesity and Metabolism · 2026

    Randomized trialOpen access · CC BYRead the open copy →

  23. Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism

    Jo Edward Lewis, Mireia Montaner, Danaé Nuzzaci et al. · Nature Metabolism · 2026

    Animal studyOpen access · CC BY3 citationsRead the open copy →

  24. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

    Rohit Seth Loomba, Jacob George, Laurent Castéra et al. · The Lancet. Gastroenterology & hepatology · 2026

    Randomized trial · Phase 2Open access · CC BY6 citationsRead the open copy →

  25. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

    Abdulhameed Alhazmi, Carel Wynand le Roux · Diabetes Obesity and Metabolism · 2026

    ReviewOpen access · CC BY-NC-ND1 citationsRead the open copy →

  26. Efektivitas Obat Generasi Baru (Amylin-based, CagriSema) dalam Mengelola Obesitas sebagai Penyakit Kronis

    Yoga Prasetyo, Zahra Mutiara Salsabila · MUARA KESEHATAN Jurnal Ilmiah Ilmu Kesehatan · 2026

    Open access · CC BY-SARead the open copy →

  27. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo

    Mohammad Yaseen, Akmal Ameer, Zulfiqar Ali et al. · Annals of Medicine and Surgery · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  28. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

    Kailei Nong, Qingyang Shi, Xinran Xie et al. · BMJ · 2026

    Systematic reviewOpen access · CC BY-NC10 citationsRead the open copy →

  29. Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes

    Walter Gulisano, Gitte Ter-Borch, Paul Brown et al. · Journal of Diabetes Science and Technology · 2026

    Open accessRead the open copy →

  30. A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance

    Mette Q. Ludwig, Bernd Coester, Desiree Gordian et al. · Nature Metabolism · 2026

    Study in humansOpen access · CC BY5 citationsRead the open copy →

  31. 1321-OR: Superior Quality of Weight Loss with a Novel Unimolecular Tetra-Agonist Peptide Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors vs. Tirzepatide and Cagrisema in Diet-Induced Obese Rats

    Soumitra S. Ghosh, BEATRIZ HERRERO, M. Pilar Valdecantos et al. · Diabetes · 2026

  32. Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

    John B. Buse, HARPREET SINGH BAJAJ, Stine‐Mathilde Dalskov et al. · The Lancet Diabetes & Endocrinology · 2026

    Randomized trial · Phase 315 citations

  33. Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

    Vanita R. Aroda, Raffaella Buzzetti, Stine‐Mathilde Dalskov et al. · The Lancet Diabetes & Endocrinology · 2026

    Randomized trial · Phase 35 citations

  34. Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

    Julio Rosenstock, Liana K. Billings, Reena Gajria et al. · The Lancet · 2026

    Randomized trial · Phase 311 citations

  35. 1228-OR: First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

    Ayna Baladi Nejad, JOHN BOLAND, Alan H. Hand et al. · Diabetes · 2026

  36. Cagrilintide–semaglutide: a new option for patients with type 2 diabetes

    André Jacques Scheen · The Lancet Diabetes & Endocrinology · 2026

  37. AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY

    Nikolinka Koleva, Boris Dinkov, Galya Stavreva · Journal of IMAB - Annual Proceeding (Scientific Papers) · 2026

    Open access · CC BY-SARead the open copy →

  38. 1766-P: VRB-103 Is a Potent, Orally Bioavailable Amylin Analog with a Strong Selectivity towards Human Amylin Receptors vs. Calcitonin Receptor

    Martijn Fenaux, Catherine L. Jones, WEIDONG ZHONG et al. · Diabetes · 2026

  39. 3078-LB: HM17321, a Novel UCN2 Analog, Improves Weight Loss Quality in Combination with Amylin Analogs in DIO Rats

    YOHAN KIM, SEON MYEONG LEE, EUNSEON KIM et al. · Diabetes · 2026

  40. 1035-OR: Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity

    NIKOLAJ BAK, MERITA ALEX, Søren A. Fuglsang et al. · Diabetes · 2026

Each list shows up to 40 papers.See all 164 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.